Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors

Virology Journal

Volumn 9, Issue , 2012, Pages

  Andrabi, Raiees ^a   Kumar, Rajesh ^a   Bala, Manju ^c   Nair, Ambili ^a   Biswas, Ashutosh ^a   Wig, Naveet ^a   Kumar, Pratik ^b   Pal, Rahul ^d   Sinha, Subrata ^e   Luthra, Kalpana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

^c SAFDARJUNG HOSPITAL   (India)

^d NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^e NATIONAL BRAIN RESEARCH CENTRE   (India)

Author keywords

Anti V3 monoclonal antibodies; Envelope glycoprotein; HIV 1; Third variable region; Viral neutralization

Indexed keywords

CHOLERA TOXIN B V3C FUSION PROTEIN; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY 277; MONOCLONAL ANTIBODY 903; MONOCLONAL ANTIBODY 904; UNCLASSIFIED DRUG; V3 PROTEIN; VIRUS GLYCOPROTEIN;

ADULT; ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INDIAN; MALE; NONHUMAN; VIRUS CULTURE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; MIDDLE AGED; YOUNG ADULT;

HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866037203     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-196     Document Type: Article

References (73)

1. Core structure of gp41 from the HIV envelope glycoprotein. Chan DC, Fass D, Berger JM, et al. Cell 1997 89 263 73 10.1016/S0092-8674(00)80205-6 9108481
2. GP120: target for neutralizing HIV-1 antibodies. Pantophlet R, Burton DR, Annu Rev Immunol 2006 24 739 69 10.1146/annurev.immunol.24.021605.090557 16551265
3. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Montero M, van Houten NE, Wang X, et al. Microbiol Mol Biol Rev 2008 72 54 84 table of contents 10.1128/MMBR.00020-07 18322034
4. The role of antibodies in HIV vaccines. Mascola JR, Montefiori DC, Annu Rev Immunol 2010 28 413 44 10.1146/annurev-immunol-030409-101256 20192810
5. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Dalgleish AG, Beverley PC, Clapham PR, et al. Nature 1984 312 763 7 10.1038/312763a0 6096719
6. Identification of a major co-receptor for primary isolates of HIV-1. Deng H, Liu R, Ellmeier W, et al. Nature 1996 381 661 6 10.1038/381661a0 8649511
7. The antigenic structure of the HIV gp120 envelope glycoprotein. Wyatt R, Kwong PD, Desjardins E, et al. Nature 1998 393 705 11 10.1038/31514 9641684
8. Identifying epitopes of HIV-1 that induce protective antibodies. Zolla-Pazner S, Nat Rev Immunol 2004 4 199 210 10.1038/nri1307 15039757
9. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Walker LM, Phogat SK, Chan-Hui P-Y, et al. Science 2009 326 285 9 10.1126/science.1178746 19729618
10. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Zhou T, Georgiev I, Wu X, et al. Science 2010 329 811 7 10.1126/science.1192819 20616231
11. Appreciating HIV type 1 diversity: subtype differences in Env. Lynch RM, Shen T, Gnanakaran S, et al. AIDS Res Hum Retroviruses 2009 25 237 48 10.1089/aid.2008.0219 19327047
12. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. Stamatos NM, Mascola JR, Kalyanaraman VS, et al. J Virol 1998 72 9656 67 9811699
13. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Li Y, Migueles SA, Welcher B, et al. Nat Med 2007 13 1032 4 10.1038/nm1624 17721546
14. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. Walker LM, Simek MD, Priddy F, et al. PLoS Pathog 2010 6 1001028 10.1371/journal.ppat.1001028 20700449
15. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Binley JM, Wrin T, Korber B, et al. J Virol 2004 78 13232 52 10.1128/JVI.78.23.13232-13252.2004 15542675
16. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Wu X, Yang Z-Y, Li Y, et al. Science 2010 329 856 61 10.1126/science.1187659 20616233
17. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Pejchal R, Doores KJ, Walker LM, et al. Science 2011 334 1097 103 10.1126/science.1213256 21998254
18. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. Gorny MK, VanCott TC, Hioe C, et al. J Immunol 1997 159 5114 22 9366441
19. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. Gorny MK, Williams C, Volsky B, et al. J Virol 2006 80 6865 72 10.1128/JVI.02202-05 16809292
20. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Stanfield RL, Gorny MK, Williams C, et al. Structure 2004 12 193 204 14962380
21. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. Hioe CE, Wrin T, Seaman MS, et al. PLoS One 2010 5 10254 10.1371/journal.pone.0010254 20421997
22. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Scheid JF, Mouquet H, Ueberheide B, et al. Science 2011 333 1633 7 10.1126/science.1207227 21764753
23. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Kwong PD, Wyatt R, Robinson J, et al. Nature 1998 393 648 59 10.1038/31405 9641677
24. Structure of a V3-containing HIV-1 gp120 core. Huang C, Tang M, Zhang M-Y, et al. Science 2005 310 1025 8 10.1126/science.1118398 16284180
25. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120. Boudet F, Girard M, Theze J, et al. Int Immunol 1992 4 283 94 10.1093/intimm/4.2.283 1377948
26. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. Vogel T, Kurth R, Norley S, J Immunol 1994 153 1895 904 7519220
27. Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity. Fenouillet E, Blanes N, Benjouad A, et al. Clin Exp Immunol 1995 99 419 24 7533680
28. Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence. Andrabi R, Choudhary AK, Bala M, et al. Arch Virol 2011 156 1787 94 10.1007/s00705-011-1053-5 21735212
29. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Javaherian K, Langlois AJ, McDanal C, et al. Proc Natl Acad Sci USA 1989 86 6768 72 10.1073/pnas.86.17.6768 2771954
30. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Goudsmit J, Debouck C, Meloen RH, et al. Proc Natl Acad Sci USA 1988 85 4478 82 10.1073/pnas.85.12.4478 2454471
31. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Palker TJ, Clark ME, Langlois AJ, et al. Proc Natl Acad Sci USA 1988 85 1932 6 10.1073/pnas.85.6.1932 2450351
32. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. Korber BT, MacInnes K, Smith RF, et al. J Virol 1994 68 6730 44 8084005
33. Diversity considerations in HIV-1 vaccine selection. Gaschen B, Taylor J, Yusim K, et al. Science 2002 296 2354 60 10.1126/science.1070441 12089434
34. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Shioda T, Levy JA, Cheng-Mayer C, Proc Natl Acad Sci USA 1992 89 9434 8 10.1073/pnas.89.20.9434 1409653
35. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. Cardozo T, Kimura T, Philpott S, et al. AIDS Res Hum Retroviruses 2007 23 415 26 10.1089/aid.2006.0130 17411375
36. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. Gorny MK, Revesz K, Williams C, et al. J Virol 2004 78 2394 404 10.1128/JVI.78.5.2394- 2404.2004 14963135
37. Structural conservation predominates over sequence variability in the crown of HIV type 1s V3 loop. Almond D, Kimura T, Kong X, et al. AIDS Res Hum Retroviruses 2010 26 717 23 10.1089/aid.2009.0254 20560796
38. Conserved structural elements in the V3 crown of HIV-1 gp120. Jiang X, Burke V, Totrov M, et al. Nat Struct Mol Biol 2010 17 955 61 10.1038/nsmb.1861 20622876
39. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. Krachmarov C, Pinter A, Honnen WJ, et al. J Virol 2005 79 780 90 10.1128/JVI.79.2.780-790.2005 15613306
40. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. Zolla-Pazner S, Zhong P, Revesz K, et al. AIDS Res Hum Retroviruses 2004 20 1254 8 10.1089/aid.2004.20.1254 15588347
41. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. Zolla-Pazner S, Kong X-P, Jiang X, et al. J Virol 2011 85 9887 98 10.1128/JVI.05086-11 21795338
42. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. Hemelaar J, Gouws E, Ghys PD, et al. AIDS 2006 20 13 23 10.1097/01.aids.0000247564.73009.bc 17053344
43. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. Nyambi PN, Mbah HA, Burda S, et al. J Virol 2000 74 7096 107 10.1128/JVI.74.15.7096-7107.2000 10888650
44. A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1. Nyambi PN, Burda S, Bastiani L, et al. J Immunol Methods 2001 253 253 62 10.1016/S0022-1759(01) 00384-2 11384686
45. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. Mascola JR, Louder MK, Winter C, et al. J Virol 2002 76 4810 21 10.1128/JVI.76.10.4810-4821.2002 11967298
46. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. Pinter A, Honnen WJ, He Y, et al. J Virol 2004 78 5205 15 10.1128/JVI.78.10.5205-5215.2004 15113902
47. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. Gorny MK, Williams C, Volsky B, et al. J Virol 2002 76 9035 45 10.1128/JVI.76.18.9035-9045.2002 12186887
48. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Zolla-Pazner S, Cohen S, Pinter A, et al. Virology 2009 392 82 93 10.1016/j.virol.2009.05.039 19632700
49. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Moseri A, Tantry S, Sagi Y, et al. Virology 2010 401 293 304 10.1016/j.virol.2010.03.007 20347111
50. Generation of human monoclonal antibodies to human immunodeficiency virus. Gorny MK, Gianakakos V, Sharpe S, et al. Proc Natl Acad Sci USA 1989 86 1624 8 10.1073/pnas.86.5.1624 2922401
51. Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. Malaspina A, Moir S, Kottilil S, et al. J Immunol 2003 170 5965 72 12794123
52. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. Birx DL, Redfield RR, Tosato G, N Engl J Med 1986 314 874 9 10.1056/NEJM198604033141403 3005862
53. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. Yarchoan R, Redfield RR, Broder S, J Clin Invest 1986 78 439 47 10.1172/JCI112595 3016028
54. Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C. Felsövályi K, Nádas A, Zolla-Pazner S, et al. AIDS Res Hum Retroviruses 2006 22 703 8 10.1089/aid.2006.22.703 16831095
55. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. Patel MB, Hoffman NG, Swanstrom R, J Virol 2008 82 903 16 10.1128/JVI.01444-07 18003735
56. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Zwart G, Langedijk H, van der Hoek L, et al. Virology 1991 181 481 9 10.1016/0042-6822(91)90880-K 2014634
57. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. Stanfield RL, Gorny MK, Zolla-Pazner S, et al. J Virol 2006 80 6093 105 10.1128/JVI.00205-06 16731948
58. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. Bell CH, Pantophlet R, Schiefner A, et al. J Mol Biol 2008 375 969 78 10.1016/j.jmb.2007.11.013 18068724
59. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Gorny MK, Wang X-H, Williams C, et al. Mol Immunol 2009 46 917 26 10.1016/j.molimm.2008.09.005 18952295
60. Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. Gorny MK, Sampson J, Li H, et al. PLoS One 2011 6 27780 10.1371/journal.pone.0027780 22164215
61. Antibody neutralization and escape by HIV-1. Wei X, Decker JM, Wang S, et al. Nature 2003 422 307 12 10.1038/nature01470 12646921
62. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Davis KL, Gray ES, Moore PL, et al. Virology 2009 387 414 26 10.1016/j.virol.2009.02.022 19298995
63. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Totrov M, Jiang X, Kong X-P, et al. Virology 2010 405 513 23 10.1016/j.virol.2010.06.027 20663531
64. Envelope glycoprotein 120 sequences of primary HIV type 1 isolates from Pune and New Delhi, India. Tripathy S, Renjifo B, Wang WK, et al. AIDS Res Hum Retroviruses 1996 12 1199 202 10.1089/aid.1996.12.1199 8844026
65. Subtypes of HIV type 1 circulating in India: partial envelope sequences. Maitra A, Singh B, Banu S, et al. AIDS Res Hum Retroviruses 1999 15 941 4 10.1089/088922299310656 10408731
66. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Gorny MK, Xu JY, Gianakakos V, et al. Proc Natl Acad Sci USA 1991 88 3238 42 10.1073/pnas.88.8.3238 2014246
67. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Traggiai E, Becker S, Subbarao K, et al. Nat Med 2004 10 871 5 10.1038/nm1080 15247913
68. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. Gigler A, Dorsch S, Hemauer A, et al. J Virol 1999 73 1974 9 9971777
69. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Marks JD, Tristem M, Karpas A, et al. Eur J Immunol 1991 21 985 91 10.1002/eji.1830210419 2019291
70. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins. Gorny MK, VanCott TC, Williams C, et al. Virology 2000 267 220 8 10.1006/viro.1999.0095 10662617
71. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. Nyambi PN, Gorny MK, Bastiani L, et al. J Virol 1998 72 9384 91 9765494
72. Mascola, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Li M, Gao F, John R, J Virol 2005 79 10108 25 10.1128/JVI.79.16.10108-10125.2005 16051804
73. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. Seaman MS, Janes H, Hawkins N, et al. J Virol 2010 84 1439 52 10.1128/JVI.02108-09 19939925